Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism

Blood

Volumn 113, Issue 18, 2009, Pages 4300-4308

  Secchiero, Paola ^a   Melloni, Elisabetta ^a   Di Iasio, Maria Grazia ^a   Tiribelli, Mario ^b   Rimondi, Erika ^a   Corallini, Federica ^a   Gattei, Valter ^c   Zauli, Giorgio ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; GAMMA SECRETASE INHIBITOR; L 685458; MESSENGER RNA; NOTCH1 RECEPTOR; NUTLIN 3; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CARBAMIC ACID DERIVATIVE; DIPEPTIDE; IMIDAZOLE DERIVATIVE; NOTCH1 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; SECRETASE; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELL MATURATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MYELOID LEUKEMIA; NEGATIVE FEEDBACK; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; UPREGULATION; WILD TYPE; APOPTOSIS; CELL DIFFERENTIATION; CELL STRAIN HL 60; CYTOLOGY; DRUG ANTAGONISM; DRUG COMBINATION; DRUG POTENTIATION; FEEDBACK SYSTEM; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEREOISOMERISM; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID PRECURSOR PROTEIN SECRETASES; APOPTOSIS; BLOTTING, WESTERN; CARBAMATES; CELL DIFFERENTIATION; DIPEPTIDES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEEDBACK, BIOCHEMICAL; FEMALE; HL-60 CELLS; HUMANS; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; OSTEOCLASTS; PIPERAZINES; RECEPTOR, NOTCH1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEREOISOMERISM; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 66149108372     PISSN: 00064971     EISSN: 15280020     Source Type: None    
DOI: 10.1182/blood-2008-11-187708     Document Type: Article

References (50)

1. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Sem Cancer Biol. 2003;13:49-58.
2. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844-848.
3. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med. 2007;13:23-31.
4. Mitani N, Niwa Y, Okamoto Y. Surveyor nucleare-based detection of p53 gene mutations in haematological malignancy. Ann Clin Biochem. 2007;44(pt 6):557-559. (Pubitemid 351724640)
5. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005;106:3150-3159. (Pubitemid 41565913)
6. Stühmer T, Chatterjee M, Hildebrandt M, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood. 2005;106:3609-3617. (Pubitemid 41609200)
7. Secchiero P, Barbarotto E, Tiribelli M, et al. Functional integrity of the p53-mediated apoptotic pathway induced by the non-genotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (BCLL). Blood. 2006;107:4122-4129. (Pubitemid 43726822)
8. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood. 2006;107:4109-4114. (Pubitemid 43726820)
9. Kojma K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood. 2006;108:993-1000. (Pubitemid 44154636)
10. Saddler C, Ouillette P, Kujawski L, et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood. 2008;111:1584-1593. (Pubitemid 351213449)
11. Janz M, Stühmer T, Vassilev LT, Bargou RC. Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/ Reed-Sternberg cells. Leukemia. 2007;21:772-779. (Pubitemid 46444562)
12. Drakos E, Thomaides A, Medeiros LJ, et al. Inhibition of p53-murine double minute 2 interaction by nutlin-3a stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res. 2007;13:3380-3387. (Pubitemid 46944926)
13. Sarek G, Ojala PM. p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo: new hope for treating aggressive viral lymphomas. Cell Cycle. 2007;6:2205-2209. (Pubitemid 47547693)
14. Petre CE, Sin SH, Dittmer DP. Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy. J Virol. 2007;8:1912-1922.
15. Secchiero P, di Iasio MG, Gonelli A, Zauli G. The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr Pharm Des. 2008;14:2100-2110.
16. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24:2899-2908.
17. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2:594-604. (Pubitemid 37328926)
18. Arima Y, Nitta M, Kuninaka S, et al. Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J Biol Chem. 2005;280:19166-19176. (Pubitemid 41379623)
19. Steele AJ, Prentice AG, Hoffbrand AV, et al. p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. Blood. 2008;112:3827-3834.
20. Alimirah F, Panchanathan R, Panchanathan Davis FJ, Chen J, Choubey D. Restoration of p53 expression in human cancer cell lines upregulates the expression of Notch1: implications for cancer cell fate determination after genotoxic stress. Neoplasia. 2007;9:427-434. (Pubitemid 46799986)
21. Rosati E, Sabatini R, Rampino G, et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Prepublished on September 16, 2008, as DOI 10.1182/blood-2008-02-139725. (Now available as Blood. 2009;113:856-865.)
22. Jönsson JI, Xiang Z, Pettersson M, Lardelli M, Nilsson G. Distinct and regulated expression of Notch receptors in hematopoietic lineages and during myeloid differentiation. Eur J Immunol. 2001;31:3240-3247. (Pubitemid 33100515)
23. Ball DW, Leach SD. Notch in malignancy. Cancer Treat Res. 2003;115:95-121.
24. Hubmann R, Schwarzmeier JD, Shehata M, et al. Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. Blood. 2002;99:3742-3747. (Pubitemid 34534546)
25. Duechler M, Shehata M, Schwarzmeier JD, Hoelbl A, Hilgarth M, Hubmann R. Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2. Leukemia. 2005;19:260-267. (Pubitemid 40220591)
26. Hajdu M, Sebestyen A, Barna G, et al. Activity of the notch-signalling pathway in circulating human chronic lymphocytic leukaemia cells. Scand J Immunol. 2007;65:271-275. (Pubitemid 46272529)
27. Jundt F, Schwarzer R, Dörken B. Notch signaling in leukemias and lymphomas. Curr Mol Med. 2008;8:51-59.
28. Milani D, Zauli G, Rimondi E, et al. Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem. 2003;86:126-135. (Pubitemid 36753853)
29. Zauli G, Bassini A, Vitale M, et al. Thrombopoietin enhances the aIIbb3-dependent adhesion of megakaryocytic cells to fibrinogen or fibronectin through PI 3 kinase. Blood. 1997;89:883-895. (Pubitemid 27121281)
30. Zauli G, Rimondi E, Nicolin V, Melloni E, Celeghini C, Secchiero P. TNF-related apoptosis inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood. 2004;104:2044-2050. (Pubitemid 39297855)
31. Zauli G, Rimondi E, Stea S, et al. TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in preosteoclast precursors. J Cell Physiol. 2008;214:117-125 (Pubitemid 350220065)
32. Chou T, Talalay P. Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
33. McLendon C, Xin T, Ziani-Cherif C, et al. Cell-free assays for gamma-secretase activity. FASEB J. 2000;14:2383-2386.
34. Mizutani T, Taniguchi Y, Aoki T, Hashimoto N, Honjo T. Conservation of biochemical mechanisms of signal transduction among mammalian Notch family members. Proc Natl Acad Sci U S A. 2001;98:9026-9031. (Pubitemid 32743863)
35. Palaga T, Miele L, Golde T, Osborne B. TCR-mediated Notch signaling regulates proliferation and IFN-gamma production in peripheral T cells. J Immunol. 2003;171:3019-3024. (Pubitemid 37093525)
36. Yamada T, Yamazaki H, Yamane T, et al. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. Blood. 2003;101:2227-2234. (Pubitemid 36302062)
37. Bai S, Kopan R, Zou W, et al. Notch1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. J Biol Chem. 2008;283:6509-6518.
38. Campbell C, Risueno RM, Salati S, Guezguez B, Bhatia M. Signal control of hematopoietic stem cell fate: Wnt, Notch, and Hedgehog as the usual suspects. Curr Opin Hematol. 2008;15:319-325.
39. Jundt F, Schwarzer R, Dörken B. Notch signaling in leukemias and lymphomas. Curr Mol Med. 2008;8:51-59.
40. Yugawa T, Handa K, Narisawa-Saito M, Ohno S, Fujita M, Kiyono T. Regulation of Notch1 gene expression by p53 in epithelial cells. Mol Cell Biol. 2007;27:3732-3742. (Pubitemid 46726180)
41. Mungamuri SK, Yang X, Thor AD, Somasundaram K. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 2006;66:4715-4724.
42. Kim SB, Chae GW, Lee J, et al. Activated Notch1 interacts with p53 to inhibit its phosphorylation and transactivation. Cell Death Differ. 2007;14:982-991. (Pubitemid 46629836)
43. Jin YH, Yoo KJ, Lee YH, Lee SK. Caspase 3-mediated cleavage of p21WAF/CIP1 associated with the cyclin A-cylin-dependent kinase 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells J Biol Chem. 2000;275:30256-30263.
44. Burgess AJ, Pavey S, Warrener R, et al. Upregulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol. 2001;60:828-837. (Pubitemid 32900266)
45. Secchiero P, Zerbinati C, di Iasio MG, et al. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab. 2007;8:395-403. (Pubitemid 46780067)
46. Kogoshi H, Sato T, Koyama T, Nara N, Tohda S. Gamma-secretase inhibitors suppress the growth of leukemia and lymphoma cells. Oncol Rep. 2007;18:77-80.
47. Carvajal D, Tovar C, Yang H, et al. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 2005;65:1918-1924. (Pubitemid 40478621)
48. Robert-Moreno A, Espinosa L, Sanchez MJ, de la Pompa JL, Bigas A. The notch pathway positively regulates programmed cell death during erythroid differentiation. Leukemia. 2007;21:1496-1503. (Pubitemid 46965292)
49. Ganapati U, Tan HT, Lynch M, Dolezal M, de Vos S, Gasson JC. Modeling notch signaling in normal and neoplastic hematopoiesis: global gene expression profiling in response to activated notch expression. Stem Cells. 2007;25:1872-1880. (Pubitemid 47258165)
50. Zauli G, Rimondi E, Corallini F, Fadda R, Capitani S, Secchiero P. The MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts via a p53-dependent pathway. J Bone Miner Res. 2007;22:1621-1630. (Pubitemid 351229332)